Immunome, Inc. (NASDAQ:IMNM) CEO Acquires $630,183.78 in Stock

Immunome, Inc. (NASDAQ:IMNM) CEO Clay B. Siegall purchased 66,057 shares of Immunome stock in a transaction dated Thursday, November 21st. The stock was bought at an average price of $9.54 per share, with a total value of $630,183.78. Following the completion of the transaction, the chief executive officer now owns 485,693 shares of the company’s stock, valued at $4,633,511.22. This represents a 15.74 % increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Immunome Price Performance

IMNM stock traded up $1.16 during mid-day trading on Monday, hitting $10.98. 351,854 shares of the stock were exchanged, compared to its average volume of 771,478. The business has a fifty day moving average price of $12.58 and a 200 day moving average price of $13.58. Immunome, Inc. has a 12 month low of $6.93 and a 12 month high of $30.96. The stock has a market capitalization of $685.37 million, a price-to-earnings ratio of -1.38 and a beta of 1.82.

Institutional Trading of Immunome

A number of hedge funds have recently bought and sold shares of the company. Arizona State Retirement System lifted its stake in Immunome by 9.2% in the second quarter. Arizona State Retirement System now owns 10,862 shares of the company’s stock worth $131,000 after purchasing an additional 918 shares during the last quarter. Clear Creek Financial Management LLC boosted its holdings in Immunome by 18.2% during the 2nd quarter. Clear Creek Financial Management LLC now owns 26,188 shares of the company’s stock valued at $317,000 after acquiring an additional 4,035 shares during the period. AQR Capital Management LLC boosted its holdings in Immunome by 34.6% during the 2nd quarter. AQR Capital Management LLC now owns 16,064 shares of the company’s stock valued at $194,000 after acquiring an additional 4,129 shares during the period. Cerity Partners LLC grew its position in Immunome by 10.5% during the 3rd quarter. Cerity Partners LLC now owns 53,103 shares of the company’s stock worth $776,000 after acquiring an additional 5,043 shares during the last quarter. Finally, Quest Partners LLC purchased a new position in Immunome in the 2nd quarter worth approximately $81,000. Institutional investors own 44.58% of the company’s stock.

Analyst Ratings Changes

Several research analysts have commented on the company. Stephens assumed coverage on Immunome in a research note on Friday, November 8th. They issued an “overweight” rating and a $30.00 target price for the company. Piper Sandler reduced their price objective on shares of Immunome from $23.00 to $21.00 and set an “overweight” rating for the company in a research note on Thursday, November 14th. Finally, Wedbush reiterated an “outperform” rating and issued a $33.00 target price on shares of Immunome in a research note on Friday, October 25th. Seven investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the company presently has a consensus rating of “Buy” and a consensus price target of $28.83.

About Immunome

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.